Cargando…

The proteome and phosphoproteome of circulating extracellular vesicle-enriched preparations are associated with characteristic clinical features in type 1 diabetes

INTRODUCTION: There are no validated clinical or laboratory biomarkers to identify and differentiate endotypes of type 1 diabetes (T1D) or the risk of progression to chronic complications. Extracellular vesicles (EVs) have been studied as biomarkers in several different disease states but have not b...

Descripción completa

Detalles Bibliográficos
Autores principales: Casu, Anna, Nunez Lopez, Yury O., Yu, Gongxin, Clifford, Christopher, Bilal, Anika, Petrilli, Alejandra M., Cornnell, Heather, Carnero, Elvis Alvarez, Bhatheja, Ananya, Corbin, Karen D., Iliuk, Anton, Maahs, David M., Pratley, Richard E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10417723/
https://www.ncbi.nlm.nih.gov/pubmed/37576973
http://dx.doi.org/10.3389/fendo.2023.1219293
_version_ 1785088106639130624
author Casu, Anna
Nunez Lopez, Yury O.
Yu, Gongxin
Clifford, Christopher
Bilal, Anika
Petrilli, Alejandra M.
Cornnell, Heather
Carnero, Elvis Alvarez
Bhatheja, Ananya
Corbin, Karen D.
Iliuk, Anton
Maahs, David M.
Pratley, Richard E.
author_facet Casu, Anna
Nunez Lopez, Yury O.
Yu, Gongxin
Clifford, Christopher
Bilal, Anika
Petrilli, Alejandra M.
Cornnell, Heather
Carnero, Elvis Alvarez
Bhatheja, Ananya
Corbin, Karen D.
Iliuk, Anton
Maahs, David M.
Pratley, Richard E.
author_sort Casu, Anna
collection PubMed
description INTRODUCTION: There are no validated clinical or laboratory biomarkers to identify and differentiate endotypes of type 1 diabetes (T1D) or the risk of progression to chronic complications. Extracellular vesicles (EVs) have been studied as biomarkers in several different disease states but have not been well studied in T1D. METHODS: As the initial step towards circulating biomarker identification in T1D, this pilot study aimed to provide an initial characterization of the proteomic and phosphoproteomic landscape of circulating EV-enriched preparations in participants with established T1D (N=10) and healthy normal volunteers (Controls) (N=7) (NCT03379792) carefully matched by age, race/ethnicity, sex, and BMI. EV-enriched preparations were obtained using EVtrap(®) technology. Proteins were identified and quantified by LC-MS analysis. Differential abundance and coexpression network (WGCNA), and pathway enrichment analyses were implemented. RESULTS: The detected proteins and phosphoproteins were enriched (75%) in exosomal proteins cataloged in the ExoCarta database. A total of 181 proteins and 8 phosphoproteins were differentially abundant in participants with T1D compared to controls, including some well-known EVproteins (i.e., CD63, RAB14, BSG, LAMP2, and EZR). Enrichment analyses of differentially abundant proteins and phosphoproteins of EV-enriched preparations identified associations with neutrophil, platelet, and immune response functions, as well as prion protein aggregation. Downregulated proteins were involved in MHC class II signaling and the regulation of monocyte differentiation. Potential key roles in T1D for C1q, plasminogen, IL6ST, CD40, HLA-DQB1, HLA-DRB1, CD74, NUCB1, and SAP, are highlighted. Remarkably, WGCNA uncovered two protein modules significantly associated with pancreas size, which may be implicated in the pathogenesis of T1D. Similarly, these modules showed significant enrichment for membrane compartments, processes associated with inflammation and the immune response, and regulation of viral processes, among others. DISCUSSION: This study demonstrates the potential of proteomic and phosphoproteomic signatures of EV-enriched preparations to provide insight into the pathobiology of T1D. The WGCNA analysis could be a powerful tool to discriminate signatures associated with different pathobiological components of the disease.
format Online
Article
Text
id pubmed-10417723
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-104177232023-08-12 The proteome and phosphoproteome of circulating extracellular vesicle-enriched preparations are associated with characteristic clinical features in type 1 diabetes Casu, Anna Nunez Lopez, Yury O. Yu, Gongxin Clifford, Christopher Bilal, Anika Petrilli, Alejandra M. Cornnell, Heather Carnero, Elvis Alvarez Bhatheja, Ananya Corbin, Karen D. Iliuk, Anton Maahs, David M. Pratley, Richard E. Front Endocrinol (Lausanne) Endocrinology INTRODUCTION: There are no validated clinical or laboratory biomarkers to identify and differentiate endotypes of type 1 diabetes (T1D) or the risk of progression to chronic complications. Extracellular vesicles (EVs) have been studied as biomarkers in several different disease states but have not been well studied in T1D. METHODS: As the initial step towards circulating biomarker identification in T1D, this pilot study aimed to provide an initial characterization of the proteomic and phosphoproteomic landscape of circulating EV-enriched preparations in participants with established T1D (N=10) and healthy normal volunteers (Controls) (N=7) (NCT03379792) carefully matched by age, race/ethnicity, sex, and BMI. EV-enriched preparations were obtained using EVtrap(®) technology. Proteins were identified and quantified by LC-MS analysis. Differential abundance and coexpression network (WGCNA), and pathway enrichment analyses were implemented. RESULTS: The detected proteins and phosphoproteins were enriched (75%) in exosomal proteins cataloged in the ExoCarta database. A total of 181 proteins and 8 phosphoproteins were differentially abundant in participants with T1D compared to controls, including some well-known EVproteins (i.e., CD63, RAB14, BSG, LAMP2, and EZR). Enrichment analyses of differentially abundant proteins and phosphoproteins of EV-enriched preparations identified associations with neutrophil, platelet, and immune response functions, as well as prion protein aggregation. Downregulated proteins were involved in MHC class II signaling and the regulation of monocyte differentiation. Potential key roles in T1D for C1q, plasminogen, IL6ST, CD40, HLA-DQB1, HLA-DRB1, CD74, NUCB1, and SAP, are highlighted. Remarkably, WGCNA uncovered two protein modules significantly associated with pancreas size, which may be implicated in the pathogenesis of T1D. Similarly, these modules showed significant enrichment for membrane compartments, processes associated with inflammation and the immune response, and regulation of viral processes, among others. DISCUSSION: This study demonstrates the potential of proteomic and phosphoproteomic signatures of EV-enriched preparations to provide insight into the pathobiology of T1D. The WGCNA analysis could be a powerful tool to discriminate signatures associated with different pathobiological components of the disease. Frontiers Media S.A. 2023-07-28 /pmc/articles/PMC10417723/ /pubmed/37576973 http://dx.doi.org/10.3389/fendo.2023.1219293 Text en Copyright © 2023 Casu, Nunez Lopez, Yu, Clifford, Bilal, Petrilli, Cornnell, Carnero, Bhatheja, Corbin, Iliuk, Maahs and Pratley https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Endocrinology
Casu, Anna
Nunez Lopez, Yury O.
Yu, Gongxin
Clifford, Christopher
Bilal, Anika
Petrilli, Alejandra M.
Cornnell, Heather
Carnero, Elvis Alvarez
Bhatheja, Ananya
Corbin, Karen D.
Iliuk, Anton
Maahs, David M.
Pratley, Richard E.
The proteome and phosphoproteome of circulating extracellular vesicle-enriched preparations are associated with characteristic clinical features in type 1 diabetes
title The proteome and phosphoproteome of circulating extracellular vesicle-enriched preparations are associated with characteristic clinical features in type 1 diabetes
title_full The proteome and phosphoproteome of circulating extracellular vesicle-enriched preparations are associated with characteristic clinical features in type 1 diabetes
title_fullStr The proteome and phosphoproteome of circulating extracellular vesicle-enriched preparations are associated with characteristic clinical features in type 1 diabetes
title_full_unstemmed The proteome and phosphoproteome of circulating extracellular vesicle-enriched preparations are associated with characteristic clinical features in type 1 diabetes
title_short The proteome and phosphoproteome of circulating extracellular vesicle-enriched preparations are associated with characteristic clinical features in type 1 diabetes
title_sort proteome and phosphoproteome of circulating extracellular vesicle-enriched preparations are associated with characteristic clinical features in type 1 diabetes
topic Endocrinology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10417723/
https://www.ncbi.nlm.nih.gov/pubmed/37576973
http://dx.doi.org/10.3389/fendo.2023.1219293
work_keys_str_mv AT casuanna theproteomeandphosphoproteomeofcirculatingextracellularvesicleenrichedpreparationsareassociatedwithcharacteristicclinicalfeaturesintype1diabetes
AT nunezlopezyuryo theproteomeandphosphoproteomeofcirculatingextracellularvesicleenrichedpreparationsareassociatedwithcharacteristicclinicalfeaturesintype1diabetes
AT yugongxin theproteomeandphosphoproteomeofcirculatingextracellularvesicleenrichedpreparationsareassociatedwithcharacteristicclinicalfeaturesintype1diabetes
AT cliffordchristopher theproteomeandphosphoproteomeofcirculatingextracellularvesicleenrichedpreparationsareassociatedwithcharacteristicclinicalfeaturesintype1diabetes
AT bilalanika theproteomeandphosphoproteomeofcirculatingextracellularvesicleenrichedpreparationsareassociatedwithcharacteristicclinicalfeaturesintype1diabetes
AT petrillialejandram theproteomeandphosphoproteomeofcirculatingextracellularvesicleenrichedpreparationsareassociatedwithcharacteristicclinicalfeaturesintype1diabetes
AT cornnellheather theproteomeandphosphoproteomeofcirculatingextracellularvesicleenrichedpreparationsareassociatedwithcharacteristicclinicalfeaturesintype1diabetes
AT carneroelvisalvarez theproteomeandphosphoproteomeofcirculatingextracellularvesicleenrichedpreparationsareassociatedwithcharacteristicclinicalfeaturesintype1diabetes
AT bhathejaananya theproteomeandphosphoproteomeofcirculatingextracellularvesicleenrichedpreparationsareassociatedwithcharacteristicclinicalfeaturesintype1diabetes
AT corbinkarend theproteomeandphosphoproteomeofcirculatingextracellularvesicleenrichedpreparationsareassociatedwithcharacteristicclinicalfeaturesintype1diabetes
AT iliukanton theproteomeandphosphoproteomeofcirculatingextracellularvesicleenrichedpreparationsareassociatedwithcharacteristicclinicalfeaturesintype1diabetes
AT maahsdavidm theproteomeandphosphoproteomeofcirculatingextracellularvesicleenrichedpreparationsareassociatedwithcharacteristicclinicalfeaturesintype1diabetes
AT pratleyricharde theproteomeandphosphoproteomeofcirculatingextracellularvesicleenrichedpreparationsareassociatedwithcharacteristicclinicalfeaturesintype1diabetes
AT casuanna proteomeandphosphoproteomeofcirculatingextracellularvesicleenrichedpreparationsareassociatedwithcharacteristicclinicalfeaturesintype1diabetes
AT nunezlopezyuryo proteomeandphosphoproteomeofcirculatingextracellularvesicleenrichedpreparationsareassociatedwithcharacteristicclinicalfeaturesintype1diabetes
AT yugongxin proteomeandphosphoproteomeofcirculatingextracellularvesicleenrichedpreparationsareassociatedwithcharacteristicclinicalfeaturesintype1diabetes
AT cliffordchristopher proteomeandphosphoproteomeofcirculatingextracellularvesicleenrichedpreparationsareassociatedwithcharacteristicclinicalfeaturesintype1diabetes
AT bilalanika proteomeandphosphoproteomeofcirculatingextracellularvesicleenrichedpreparationsareassociatedwithcharacteristicclinicalfeaturesintype1diabetes
AT petrillialejandram proteomeandphosphoproteomeofcirculatingextracellularvesicleenrichedpreparationsareassociatedwithcharacteristicclinicalfeaturesintype1diabetes
AT cornnellheather proteomeandphosphoproteomeofcirculatingextracellularvesicleenrichedpreparationsareassociatedwithcharacteristicclinicalfeaturesintype1diabetes
AT carneroelvisalvarez proteomeandphosphoproteomeofcirculatingextracellularvesicleenrichedpreparationsareassociatedwithcharacteristicclinicalfeaturesintype1diabetes
AT bhathejaananya proteomeandphosphoproteomeofcirculatingextracellularvesicleenrichedpreparationsareassociatedwithcharacteristicclinicalfeaturesintype1diabetes
AT corbinkarend proteomeandphosphoproteomeofcirculatingextracellularvesicleenrichedpreparationsareassociatedwithcharacteristicclinicalfeaturesintype1diabetes
AT iliukanton proteomeandphosphoproteomeofcirculatingextracellularvesicleenrichedpreparationsareassociatedwithcharacteristicclinicalfeaturesintype1diabetes
AT maahsdavidm proteomeandphosphoproteomeofcirculatingextracellularvesicleenrichedpreparationsareassociatedwithcharacteristicclinicalfeaturesintype1diabetes
AT pratleyricharde proteomeandphosphoproteomeofcirculatingextracellularvesicleenrichedpreparationsareassociatedwithcharacteristicclinicalfeaturesintype1diabetes